JAMES WEIDEL: Open Payments
NPI 1073790564 · CATSKILL, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,759 in 100 payments from 12 companies in 2025. Trend: 2023 $345 · 2024 $597 · 2025 $1,759
Food & beverage: $1,759
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $327 |
| E.R. Squibb & Sons, L.L.C. | 16 | $242 |
| Vanda Pharmaceuticals Inc. | 12 | $235 |
| Alkermes, Inc. | 16 | $214 |
| ABBVIE INC. | 11 | $196 |
| Otsuka America Pharmaceutical, Inc. | 9 | $181 |
| Axsome Therapeutics, Inc. | 10 | $154 |
| Supernus Pharmaceuticals, Inc. | 5 | $100 |
| Braeburn Inc. | 2 | $36 |
| Janssen Pharmaceuticals, Inc | 2 | $30 |
Products named: CAPLYTA, COBENFY, FANAPT, ARISTADA, REXULTI, VRAYLAR, Auvelity, Qelbree.
Industry payments across NY — which companies pay providers there.
